Stock Taper 
FBIO
$2.77
▼ DOWN 1.07% (-0.03)
KEY STATISTICS
Market Cap$92.02 M
52w High$4.53
52w Low$2.18
Dividend Yield—
Frequency—
P/E1.23
Volume309.56K
Shares Out.33.22M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Lindsay Allan Rosenwald
COMPENSATION 2026
Salary$62,665
Stock Awards$1,103,032
Incentive Plan Pay$0
All Other Comp.$150,000
Total$1,380,197
ABOUT
SECTOR
Healthcare
WENT PUBLIC
November 17, 2011
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
78
PRICE TARGET
Target High$5.00
Target Low$5.00
Target Median$5.00
Target Consensus$5.00
UPCOMING EARNINGS
DateNov 16, 2026
DayMonday
Rev. Est.$21.57M
NOV
16
MON
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-10-10 | Reverse | 1:15 |
PRICE
$2.77 ▼ DOWN 1.07% (−$0.03)About Fortress Biotech, Inc.
https://www.fortressbiotech.com ↗Fortress Biotech, Inc. develops and commercializes dermatology and biopharmaceutical products, including treatments for acne, skin conditions, wounds, cancers, and rare diseases, with a pipeline of late-stage, early-stage, and preclinical candidat...
INDUSTRY
Biotechnology
A PRODUCT FORTRESS BIOTECH, INC. IS KNOWN FOR
ZYCUBO® (copper histidinate)
ZYCUBO®, FDA-approved in January 2026, is the first subcutaneous injectable treatment for Menkes disease, significantly improving survival rates and marking a major milestone for Fortress Biotech and affected patients.
Revenue by Products
| Icon | PRODUCT | Q4-2024 | Q2-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
 | Qbrexza | $13.26M | $6.95M ▼ | $5.03M ▼ | $5.11M ▲ |
 | Accutane | $7.87M | $3.4M ▼ | $3.31M ▼ | $3.36M ▲ |
 | Amzeeq | $3.05M | $879K ▼ | — | — |
 | Zilxi | $1M | $256K ▼ | — | — |
ETFS HOLDING THIS STOCK
ETFS HOLDING
14
LISTED HERE
4
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
21.94%
HOLDERS
92
TOP 12 OF 92 · RANKED BY POSITION SIZE
Vanguard Group Inc
Blackrock Fund Advisors
Opaleye Management Inc.
Cpwm, LLC
Opus Point Partners Management, LLC
Belmont Global Advisors, Inc.
Summit Financial, LLC
Blackrock Institutional Trust Company, N.A.
Susquehanna International Group, Llp
Pvg Asset Management Corp
Shikiar Asset Management Inc
Geode Capital Management, LLC
RATINGS SNAPSHOT
Overall rating: A-
Discounted Cash Flow1
Return On Equity5
Return On Assets5
Debt To Equity2
Price To Earnings3
Price To Book5
Overall Score4
INSIDER TRADES
★
OFFICER: CHIEF FINANCIAL OFFICER
Jin David
Purchase · 400.0K shares
2026-06-22
★
OFFICER: CHIEF FINANCIAL OFFICER
Jin David
Purchase · 3.0K shares
2026-04-01
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: PRESIDENT, CEO & CHAIRMAN
ROSENWALD LINDSAY A MD
Purchase · 475.4K shares
2026-03-18
★
DIRECTOR, OFFICER: EXECUTIVE VICE CHAIRMAN
WEISS MICHAEL S
Purchase · 475.4K shares
2026-03-18
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 RLMD | $4.33 | COMPARE |
 IMUX | $15.40 | COMPARE |
 ADAG | $3.68 | COMPARE |
 VXRT | $0.50 | COMPARE |
 GANX | $1.77 | COMPARE |
 XBIT | $2.27 | COMPARE |
 PMVP | $1.22 | COMPARE |
 NTRB | $4.46 | COMPARE |